Role of GSK-3β in Alzheimer's disease pathology

Emmanuel Planel, Xiaoyan Sun, Akihiko Takashima

Research output: Contribution to journalReview articlepeer-review

70 Scopus citations

Abstract

Glycogen synthase kinase 3β (GSK-3β) is an important regulatory kinase involved in multiple processes such as metabolic control, embryonic development, cell death, and oncogenesis. It has been found to interact with many molecules associated with Alzheimer's disease (AD) such as the microtubule-associated protein tau, presenilin 1, the amyloid-β peptide, the amyloid precursor protein, and acetylcholine. Furthermore, GSK-3β might be involved in brain aging and longevity. As GSK-3β is associated with so many components of AD pathology, we review the current data on the role of this kinase in tau hyperphosphorylation, then look at its association with AD-related molecules and pathways, and finally discuss its involvement in cell death and aging. We attempt to integrate all these data to arrive at the proposition that GSK-3β is a pivotal molecule in the evolution of AD and that developing drugs directed at this kinase might prove to be beneficial in the treatment of this devastating disease.

Original languageEnglish (US)
Pages (from-to)491-510
Number of pages20
JournalDrug Development Research
Volume56
Issue number3
DOIs
StatePublished - Jul 1 2002
Externally publishedYes

Keywords

  • APP
  • Amyloid-β
  • GSK-3β
  • Insulin
  • Kinesin
  • Neurofibrillary tangles
  • Phosphatase
  • Pro-apoptosis
  • Tau

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Role of GSK-3β in Alzheimer's disease pathology'. Together they form a unique fingerprint.

Cite this